↧
Valeant Reportedly Nearing Deal To Buy Bausch & Lomb For $9 Bln
↧
Valeant pays $8.7 billion for Bausch & Lomb
↧
↧
Valeant: FDA Rejects Nail Fungus Treatment Efinaconazole Over Container
↧
Valeant, Bausch & Lomb And The Long Reach Of Fred Hassan
↧
5 Drugs Stocks Driving The Industry Higher
TheStreet.com
↧
↧
China Biotech In Review: Valeant Pharma Gains Sales Foothold In China With Bausch & Lomb Buy
↧
Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Migranal(R) Nasal Spray
↧
Valeant To Cut To 2,850 Workers After Bausch + Lomb Deal
↧
Valeant CEO Blasted By NY Pols For Moving Bausch + Lomb HQ
↧
↧
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
↧
Which are pharma's top 4 innovators? Hint: It's not the big guys
↧
Anacor: Overvalued On Weak Drug Pipeline
TheStreet.com
↧
Valeant Pharmaceuticals Seeks to Cut Rates on $2.3 Billion Loans
Bloomberg/Businessweek
↧
↧
Actavis, Gilead, Valeant: Outlook For Health Stocks
Investors.com
↧
With $29B in deals so far, 2013 shaping up as big M&A year
↧
Good News for Valeant
Yahoo/Zacks
↧
Anacor reaches all-time high after saying it got $100M arbitration ruling in Valeant dispute
↧
↧
Canada's Valeant posts loss, cuts 2013 sales forecast
Yahoo/Reuters
↧
Drug-maker Valeant eyes small and large M&A deals
↧
Endo Tax Edge for Deals Mimics Valeant Playbook: Real M&A
↧